Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Create a living biobank of PDOs from Stage I-III lung cancer patients.
Checked against the public recordLast updated Apr 20, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Interventions being studied
- Procedure: Lung Tumor Resection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure. * Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care * Any clinical stage of lung cancer * Adult patients ≥18 years of age * Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history Exclusion Criteria: * At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UT Health San Antonio, M.D. Anderson Cancer CenterSan Antonio, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 20, 2026. Always confirm current availability with the study team.